Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma

GE Schuebbe; T Knösel; HR Dürr; M Angele; Falk Röder; S Abdel-Rahman; A Alig; RD Issels; D Di Gioia; LH Lindner

Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma

GE Schuebbe, T Knösel, HR Dürr, M Angele, Falk Röder, S Abdel-Rahman, A Alig, RD Issels, D Di Gioia, LH Lindner

Department of Radiotherapy and Radiation Oncology

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - 2018
Event	Annual Meeting of the European Society for medical Oncology (ESMO) - München, Germany Duration: 1 Jan 2018 → …

Conference with scientific content

Conference with scientific content	Annual Meeting of the European Society for medical Oncology (ESMO)
Country/Territory	Germany
City	München
Period	1/01/18 → …

1 unpublished Abstract

Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma
Schuebbe, G., Knösel, T., Dürr, H., Angele, M., Röder, F., Abdel-Rahman, S., Alig, A., Issels, R., Di Gioia, D. & Lindner, L., 2018.
Research output: Contribution to conference › unpublished Abstract

Cite this

Schuebbe, GE., Knösel, T., Dürr, HR., Angele, M., Röder, F., Abdel-Rahman, S., Alig, A., Issels, RD., Di Gioia, D., & Lindner, LH. (2018). Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma. Poster session presented at Annual Meeting of the European Society for medical Oncology (ESMO), München, Germany.

@conference{6611c2abfb294fb79639dfe68d338d86,

title = "Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma",

author = "GE Schuebbe and T Kn{\"o}sel and HR D{\"u}rr and M Angele and Falk R{\"o}der and S Abdel-Rahman and A Alig and RD Issels and {Di Gioia}, D and LH Lindner",

year = "2018",

language = "English",

note = "Annual Meeting of the European Society for medical Oncology (ESMO) ; Conference date: 01-01-2018",

}

Schuebbe, GE, Knösel, T, Dürr, HR, Angele, M, Röder, F, Abdel-Rahman, S, Alig, A, Issels, RD, Di Gioia, D & Lindner, LH 2018, 'Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma', Annual Meeting of the European Society for medical Oncology (ESMO), München, Germany, 1/01/18.

Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma. / Schuebbe, GE; Knösel, T; Dürr, HR et al.
2018. Poster session presented at Annual Meeting of the European Society for medical Oncology (ESMO), München, Germany.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma

AU - Schuebbe, GE

AU - Knösel, T

AU - Dürr, HR

AU - Angele, M

AU - Röder, Falk

AU - Abdel-Rahman, S

AU - Alig, A

AU - Issels, RD

AU - Di Gioia, D

AU - Lindner, LH

PY - 2018

Y1 - 2018

M3 - Poster

T2 - Annual Meeting of the European Society for medical Oncology (ESMO)

Y2 - 1 January 2018

ER -

Schuebbe GE, Knösel T, Dürr HR, Angele M, Röder F, Abdel-Rahman S et al.. Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma. 2018. Poster session presented at Annual Meeting of the European Society for medical Oncology (ESMO), München, Germany.